Health - US

CDC                                                                                                                Dec. 19, 2014

 The 2014 Ebola epidemic is the largest in history, affecting multiple countries in West Africa. Two imported cases, including one death, and two locally acquired cases in healthcare workers have been reported in the US. CDC and partners are taking precautions to prevent the further spread of Ebola within the US

CDC/OSTLTS Public Health Law Program and Office of the Associate Director for Policy compiled an Interim Table of State Ebola Screening and Monitoring Policies for Asymptomatic Individuals[PDF 826KB] to help law and policy makers prepare for and respond to Ebola-related situations.

See complete report.

http://www.cdc.gov/phlp/publications/topic/ebola.html

REUTERS                                                                                              Dec. 19, 2014

GENEVA –  Trials of GlaxoSmithKline's experimental Ebola vaccine are likely to move to a second phase in February, later than previously suggested, after a meeting of national regulators said they needed more information.

The World Health Organization, which hosted a meeting of national regulatory authorities and ethics committees earlier this week, said they had thoroughly discussed all aspects of the proposed trials at the two-day meeting.

"Reviewing countries requested additional documentation from the manufacturer of the vaccine, GlaxoSmithKline, before authorization of the trials," the WHO said in a statement.

Countries where the trials are planned -- Cameroon, Ghana, Mali, Nigeria and Senegal -- should receive and review the additional information by the end of January.

"If these steps are completed to the satisfaction of the national authorities, Phase II trials are likely to begin in February," the statement said.

The GSK vaccine is already undergoing Phase I trials, to check its safety in humans, in Switzerland, Britain, Mali and the United States, and is one of the two leading candidate vaccines for Ebola already undergoing tests.

NBC NEWS by Maggie Fox                                                                                                      Dec. 19, 2014

German doctors think they have another possible drug to add to the Ebola treatment pipeline. It's one already shown to be safe and in trials to treat heart attack victims.

The drug, called FX06, is made using a natural human blood-clotting protein called fibrin. The hope is it can help reduce the leaking of blood vessels that can seriously threaten people with advanced Ebola infections.

The team at Frankfurt University Hospital say it may have helped save a Ugandan doctor they treated, although they note it failed to save a second patient.

Nonetheless, it should be tested, they wrote in the Lancet medical journal.

"Even though the patient was critically ill, we were able to support him long enough for his body to start antibody production and for the virus to be cleared by his body's defenses," said Dr. Timo Wolf, who helped lead the research team. "FX06 could potentially be a valuable agent in contribution to supportive therapy."

Read complete story.

Interviews with experts on what to take away from the devastation of the disease.

THE ATLANTIC   by Julie Beck                                                                                                 Dec. 17, 2014

...While some in the Western media criticized West Africans' fear of health workers and resistance to public-health measures, the United States got a small taste of Ebola panic when Thomas Eric Duncan became the first case diagnosed in the country in September, followed by three other cases this fall. Duncan was the only patient to die in the U.S., and the panic died down quietly.